Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The price of MoonLake Immunotherapeutics (NASDAQ: MLTX) closed at $13.35 in the last session, up 6.63% from day before closing price of $12.52. In other words, the price has increased by $6.63 from its previous closing price. On the day, 1.63 million shares were traded. MLTX stock price reached its highest trading level at $13.5551 during the session, while it also had its lowest trading level at $12.49.
Ratios:
We take a closer look at MLTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.50 and its Current Ratio is at 8.50. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.26.
Goldman Downgraded its Buy to Neutral on October 01, 2025, while the target price for the stock was maintained at $7.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 08 ’25 when Bodenstedt Matthias bought 10,870 shares for $9.09 per share. The transaction valued at 98,808 led to the insider holds 627,536 shares of the business.
Chen Bihua sold 6,494,151 shares of MLTX for $46,827,628 on Sep 29 ’25. The Former 10% Owner now owns 2,000,000 shares after completing the transaction at $7.21 per share. On Sep 30 ’25, another insider, Chen Bihua, who serves as the Former 10% Owner of the company, sold 5,827 shares for $6.96 each. As a result, the insider received 40,556 and left with 1,994,173 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLTX now has a Market Capitalization of 945812800 and an Enterprise Value of 547987648.
Stock Price History:
The Beta on a monthly basis for MLTX is 1.21, which has changed by -0.7659813 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, MLTX has reached a high of $62.75, while it has fallen to a 52-week low of $5.95. The 50-Day Moving Average of the stock is -0.75%, while the 200-Day Moving Average is calculated to be -64.43%.
Shares Statistics:
According to the various share statistics, MLTX traded on average about 5.00M shares per day over the past 3-months and 1989940 shares per day over the past 10 days. A total of 63.70M shares are outstanding, with a floating share count of 62.77M. Insiders hold about 11.40% of the company’s shares, while institutions hold 60.61% stake in the company. Shares short for MLTX as of 1763078400 were 3856500 with a Short Ratio of 0.77, compared to 1760486400 on 4890713. Therefore, it implies a Short% of Shares Outstanding of 3856500 and a Short% of Float of 10.82.
Earnings Estimates
The market rating of MoonLake Immunotherapeutics (MLTX) is currently shaped by the ongoing analysis conducted by 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.89, with high estimates of -$0.68 and low estimates of -$1.01.
Analysts are recommending an EPS of between -$3.46 and -$3.69 for the fiscal current year, implying an average EPS of -$3.58. EPS for the following year is -$3.58, with 10.0 analysts recommending between -$1.83 and -$4.36.
